{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:43:15Z","timestamp":1773416595921,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T00:00:00Z","timestamp":1531526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Laboratorios del Doctor Esteve, S.A.U."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s40261-018-0672-y","type":"journal-article","created":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T08:09:44Z","timestamp":1531555784000},"page":"819-827","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Effect of Food on Tramadol and Celecoxib Bioavailability Following Oral Administration of Co-Crystal of Tramadol\u2013Celecoxib (CTC): A Randomised, Open-Label, Single-Dose, Crossover Study in Healthy Volunteers"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5953-8911","authenticated-orcid":false,"given":"Gregorio","family":"Encina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3314-5321","authenticated-orcid":false,"given":"Mercedes","family":"Encabo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4735-424X","authenticated-orcid":false,"given":"Marisol","family":"Escriche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounia","family":"Lahjou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Sicard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7694-1796","authenticated-orcid":false,"given":"Neus","family":"Gascon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8258-7671","authenticated-orcid":false,"given":"Carlos","family":"Plata-Salam\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5049-1379","authenticated-orcid":false,"given":"Sebasti\u00e1n","family":"Videla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,14]]},"reference":[{"issue":"4","key":"672_CR1","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1039\/C5CC08216A","volume":"52","author":"NK Duggirala","year":"2016","unstructured":"Duggirala NK, Perry ML, Almarsson O, Zaworotko MJ. Pharmaceutical cocrystals: along the path to improved medicines. Chem Commun (Camb). 2016;52(4):640\u201355.","journal-title":"Chem Commun (Camb)"},{"issue":"9","key":"672_CR2","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1517\/17425255.2014.942281","volume":"10","author":"N Shan","year":"2014","unstructured":"Shan N, Perry ML, Weyna DR, Zaworotko MJ. Impact of pharmaceutical cocrystals: the effects on drug pharmacokinetics. Expert Opin Drug Metab Toxicol. 2014;10(9):1255\u201371.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"672_CR3","unstructured":"European Medicines Agency. Reflection paper on the use of cocrystals of active substances in medicinal products. 2015. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/07\/WC500189927.pdf\n                    \n                  . Accessed 12 Oct 2017."},{"issue":"4","key":"672_CR4","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1021\/acs.cgd.6b01848","volume":"17","author":"C Almansa","year":"2017","unstructured":"Almansa C, Merc\u00e8 R, Tesson N, Farran J, Tom\u00e0s J, Plata-Salam\u00e1n CR. Co-Crystal of Tramadol hydrochloride\u2013Celecoxib (CTC): a novel API\u2013API co-crystal for the treatment of pain. Cryst Growth Des. 2017;17(4):1884\u201392.","journal-title":"Cryst Growth Des"},{"issue":"2","key":"672_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jpain.2015.12.008","volume":"17","author":"R Chou","year":"2016","unstructured":"Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists\u2019 Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016;17(2):131\u201357.","journal-title":"J Pain"},{"issue":"3 Suppl 1","key":"672_CR6","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1097\/01.NAJ.0000513527.71934.73","volume":"117","author":"RC Polomano","year":"2017","unstructured":"Polomano RC, Fillman M, Giordano NA, Vallerand AH, Nicely KL, Jungquist CR. Multimodal analgesia for acute postoperative and trauma-related pain. Am J Nurs. 2017;117(3 Suppl 1):S12\u201326.","journal-title":"Am J Nurs"},{"key":"672_CR7","first-page":"CD008659","volume":"9","author":"RA Moore","year":"2015","unstructured":"Moore RA, Derry S, Aldington D, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults\u2014an overview of Cochrane reviews. Cochrane Database Syst Rev. 2015;9:CD008659.","journal-title":"Cochrane Database Syst Rev"},{"key":"672_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.12703\/P7-56","volume":"7","author":"TL Yaksh","year":"2015","unstructured":"Yaksh TL, Woller SA, Ramachandran R, Sorkin LS. The search for novel analgesics: targets and mechanisms. F1000Prime Rep. 2015;7:56.","journal-title":"F1000Prime Rep"},{"key":"672_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2018.06.022","author":"M Merlos","year":"2018","unstructured":"Merlos M, Portillo-Salido E, Brenchat A, Aubel B, Buxens J, Fisas A, et al. Administration of a co-crystal of tramadol and celecoxib in a 1:1 molecular ratio produces synergistic antinociceptive effects in a postoperative pain model in rats. Eur J Pharmacol. 2018. \n                    https:\/\/doi.org\/10.1016\/j.ejphar.2018.06.022\n                    \n                  .","journal-title":"Eur J Pharmacol."},{"issue":"2","key":"672_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40268-018-0235-y","volume":"18","author":"J L\u00f3pez-Cedr\u00fan","year":"2018","unstructured":"L\u00f3pez-Cedr\u00fan J, Videla S, Burgue\u00f1o M, Ju\u00e1rez I, Aboul-Hosn S, Mart\u00edn-Granizo R, et al. Co-Crystal of Tramadol\u2013Celecoxib in patients with moderate to severe acute post-surgical oral pain: a dose-finding, randomised, double-blind, placebo- and active-controlled, multicentre, phase II trial. Drugs R&D. 2018;18(2):137\u201348.","journal-title":"Drugs R&D"},{"issue":"12","key":"672_CR11","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1111\/bcp.13395","volume":"83","author":"S Videla","year":"2017","unstructured":"Videla S, Lahjou M, Vaqu\u00e9 A, Sust M, Encabo M, Soler L, et al. Single-dose pharmacokinetics of Co-Crystal of Tramadol\u2013Celecoxib: results of a four-way randomized open-label phase I clinical trial in healthy subjects. Br J Clin Pharmacol. 2017;83(12):2718\u201328.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"672_CR12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/bcp.13428","volume":"84","author":"S Videla","year":"2018","unstructured":"Videla S, Lahjou M, Vaqu\u00e9 A, Sust M, Escriche M, Soler L, et al. Pharmacokinetics of multiple doses of Co-Crystal of Tramadol\u2013Celecoxib: findings from a 4-way randomized open-label Phase I clinical trial. Br J Clin Pharmacol. 2018;84(1):64\u201378.","journal-title":"Br J Clin Pharmacol"},{"key":"672_CR13","unstructured":"European Medicines Agency. Summary of product characteristics for tramadol hydrochloride 50\u00a0mg capsules. 2017. \n                    http:\/\/www.medicines.org.uk\/EMC\/medicine\/24186\/SPC\n                    \n                  . Accessed 12 Oct 2017."},{"key":"672_CR14","unstructured":"European Medicines Agency. Summary of product characteristics for Celebrex 100\u00a0mg capsule. 2016. \n                    http:\/\/www.medicines.org.uk\/emc\/medicine\/14534\n                    \n                  . Accessed 12 Oct 2017."},{"key":"672_CR15","unstructured":"Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review for Celebrex (celecoxib). 1999. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/99\/21156-S007_Celebrex_biopharmr.pdf\n                    \n                  . Accessed 02 Nov 2017."},{"key":"672_CR16","unstructured":"Food and Drug Administration. Guidance for industry. Food-effect bioavailability and fed bioequivalence studies. 2002. \n                    https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm070241.pdf\n                    \n                  . Accessed 06 Nov 2017."},{"key":"672_CR17","unstructured":"European Medicines Agency. Guideline on the investigation of bioequivalence. 2010. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070039.pdf\n                    \n                  . Accessed 11 Jun 2017."},{"issue":"8","key":"672_CR18","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.3109\/03639045.2015.1135935","volume":"42","author":"E Lyng","year":"2016","unstructured":"Lyng E, Havenaar R, Shastri P, Hetsco L, Vick A, Sagartz J. Increased bioavailability of celecoxib under fed versus fasted conditions is determined by postprandial bile secretion as demonstrated in a dynamic gastrointestinal model. Drug Dev Ind Pharm. 2016;42(8):1334\u20139.","journal-title":"Drug Dev Ind Pharm"},{"issue":"18","key":"672_CR19","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.2165\/11208240-000000000-00000","volume":"71","author":"PL McCormack","year":"2011","unstructured":"McCormack PL. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs. 2011;71(18):2457\u201389.","journal-title":"Drugs"},{"key":"672_CR20","unstructured":"ClinicalTrials.gov. Co-crystal E-58425 vs tramadol and celecoxib for moderate to severe acute pain after bunionectomy. Phase III clinical trial. 2017. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03108482\n                    \n                  . Accessed 18 Dec 2017."},{"key":"672_CR21","unstructured":"ClinicalTrials.gov. Efficacy and safety in a randomised acute pain study of MR308 (Tramadol\/Celecoxib). (STARDOM1). 2017. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02982161\n                    \n                  . Accessed 12 Oct 2017."},{"key":"672_CR22","unstructured":"ClinicalTrials.gov. Efficacy and safety in a randomised acute pain study of MR308. (STARDOM2). 2017. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03062644\n                    \n                  . Accessed 12 Oct 2017."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-018-0672-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0672-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0672-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T19:13:21Z","timestamp":1563045201000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-018-0672-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,14]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["672"],"URL":"https:\/\/doi.org\/10.1007\/s40261-018-0672-y","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,14]]},"assertion":[{"value":"14 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"GE, MEn, MEs, NG and CP-S are employees of Esteve Pharmaceuticals, S.A. SV was an employee of Esteve Pharmaceuticals, S.A. at the time of the clinical trial. KS is an employee of Mundipharma Research Ltd. ES and ML have no potential conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}